SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy
BiotechTV - News
00:00
TYK2/JAK1 brain-penetrant program for Parkinson's
Vlad describes a brain-penetrant TYK2/JAK1 inhibitor targeting neuroinflammation and an initiated pivotal Parkinson's trial.
Play episode from 06:17
Transcript
